Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial potential of the vaccine, which is a key part of Moderna's cancer drug pipeline. Partner Merck's stock dipped slightly, while BioNTech and Pfizer saw smaller declines or steadiness due to their more diversified portfolios. The next key step is whether the full trial data supports a regulatory filing, which will influence Moderna's stock recovery and the vaccine's market outlook.
Moderna's stock is down 8.21% at USD 183.68 on Pluang as of Oct 26, 2026 20:32 WIB, reflecting ongoing investor caution. Merck's shares show a slight decline of 0.12%, trading at USD 145.10, while BioNTech is down 2.18% at USD 86.19. Pfizer remains steady with a 0.50% gain, priced at USD 30.18 on the platform.
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
Biotech stocks are rallying strongly in 2026, with the iShares Biotechnology ETF up 24% year-to-date, building on a 28% gain in 2025. Moderna leads with a 587% surge despite a recent dip after positive cancer vaccine data leaked. The sector's growth ...
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
